Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conservative Treatments of Retinoblastoma (RETINO 2011)
NCT02866136Phase 2Active, not recruiting
- Sponsor
- Institut Curie
- Start
- Feb 2012
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan, carboplatin, etoposide, vincristine sulfate liposome injection in retinoblastoma (Rb), sponsored by Institut Curie. Started Feb 2012; status: active, not recruiting.
02
Drugs
melphalancarboplatinetoposidevincristine sulfate liposome injection
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT02866136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866136.